Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00562809 · ClinicalTrials.gov registry record · Phase 4
The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,005
- Enrollment target
NCT00562809 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 1,005 participants.
The verdict
NCT00562809, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,005 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of Irbesartan 150/12.5 mg and 300/25 mg in patients with hypertension not controlled by monotherapy.
Interventions
- DRUG IRBESARTAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,005 participants |
| Start Date | 2003-07 |
| Est. Completion | 2004-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00562809
The ClinicalTrials.gov registry entry for NCT00562809 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,005 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IRBESARTAN is the first listed.
NCT00562809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00562809 about?
NCT00562809 is a clinical study titled "The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension". The purpose of this study is to assess the efficacy and safety of Irbesartan 150/12.5 mg and 300/25 mg in patients with hypertension not controlled by monotherapy.
What is the current status of trial NCT00562809?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,005 participants. The study started on 2003-07. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00562809?
The interventions under investigation include: IRBESARTAN (DRUG).
Who is sponsoring clinical trial NCT00562809?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.